drugset
drugset / Trial / NCT03712449

A Study to Evaluate Participant Satisfaction With Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment

NCT03712449 ↗

Phase 4 Completed 59 enrolled Allergan
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to quantify the psychological and emotional impact of comprehensive aesthetic treatment with a portfolio of Allergan products by measuring the change in participant's satisfaction with facial appearance from baseline to the final study visit.

Timeline

Start
2019-01-22
Primary completion
2020-07-29
Completion
2020-07-29

Drugs

EvaluationDrugModalityDoseRoute
Subject BELKYRA Unknown 100 mg Subcutaneous
Background Botulinum toxin type A Protein / enzyme biologic 2 iu Other
Background Botulinum toxin type A Protein / enzyme biologic 6 iu Other
Background Botulinum toxin type A Protein / enzyme biologic 20 iu Other
Background Botulinum toxin type A Protein / enzyme biologic 24 iu Other

Indications

No indication recorded.